Immune response to intradermally administered Ixiaro in healthy adults

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519876-17-00

Acronym

Ixiaro i.d. - IdIx

Enrollment

240

Registered

2025-01-10

Start date

Unknown

Completion date

Unknown

Last updated

2025-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

18-64 years old volunteers with general good health

Brief summary

Measurement of levels of neutralizing serum antibodies (PRNT)..

Detailed description

-To study circulating plasmablasts (ELISPOT) and cell-mediated immuneresponses after intradermal vs. intramuscular Ixiaro. - To study adverse event profiles

Interventions

DRUGIXIARO suspension for injection Japanese encephalitis vaccine (inactivated

DRUGadsorbed)

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Measurement of levels of neutralizing serum antibodies (PRNT)..	—

Secondary

Measure	Time frame
-To study circulating plasmablasts (ELISPOT) and cell-mediated immuneresponses after intradermal vs. intramuscular Ixiaro. - To study adverse event profiles	—

Countries

Finland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026